Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

MorphoSys, Incyte Say Monjuvi Added to Cancer Network's Clinical Practice Guidelines for B-cell Lymphomas

4:33AM ET 8/19/2020 MT Newswires
MorphoSys AG (MOR) and Incyte (INCY) said Tuesday that Monjuvi has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell lymphomas.

Specifically, the drug has been granted a Category 2a designation in combination with lenalidomide as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

NCCN is a network of 30 leading cancer centers devoted to patient care, research and education. Its guidelines aim to aid the decision-making process of individuals involved in cancer care.

The drug has been developed under a clinical collaboration between MorphoSys and Incyte and is currently approved in the US in combination with lenalidomide for the treatment of adults with relapsed or refractory DLBCL.

Price: 31.97, Change: -0.63, Percent Change: -1.93